74 slides from Beone Medicines Ltd. Class A's technical presentation, Aug 26, 2021
Slide 1: R&D Update, August 25, 2021
1 August 25, 2021 R & D U P DAT E Exhibit 99.1
Slide 2: Disclosures
2 DISCLOSURES Certain statements contained in this presentation and in the accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements reg
Slide 3: Today's Agenda
3 TODAY’S AGENDA Welcome and Introduction: Creating an Ecosystem of Innovation John V. Oyler Our Scientific Ecosystem of Excellence Xiaodong Wang R&D Capability and Portfolio Overview Lai Wang, Ph.D. Hematology Oncology Clinical Program Update William Novotny, M.D. Solid Tumor Clinical Program Updat
Slide 4: Creating an Ecosystem of Innovation
4 CREATING AN ECOSYSTEM OF INNOVATION John V. Oyler Co-Founder, Chairman and CEO
Slide 5: Our Mission: Patients First Through Science and Affordability
5 Help transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world through science and business innovation OUR MISSION: PATIENTS FIRST THROUGH SCIENCE AND AFFORDABILITY
Slide 6: Once-in-a-lifetime opportunity to accelerate global development
6 WE SAW THE ONCE-IN-A-LIFETIME OPPORTUNITY TO ACCELERATE GLOBAL DEVELOPMENT 10+ YEARS AGO… Internal, global, and modernized efficiency of clinical science to create time and cost advantages and broaden patient access
Slide 7: Building a Global Ecosystem of Cost and Speed Competitive Advantages
7 BUILDING A GLOBAL ECOSYSTEM OF COST AND SPEED COMPETITIVE ADVANTAGES Innovation with speed and lower cost to better serve patients around the world FULLY INTEGRATED END-TO-END ~7,000 COLLEAGUES - 5 CONTINENTS - 17 GEOGRAPHIES • One of world’s largest oncology teams (650+) with 50+ preclinical prog
Slide 8: Our Scientific Ecosystem of Excellence
8 Xiaodong Wang, Ph.D. Co-Founder & Chairman of Scientific Advisory Board OUR SCIENTIFIC ECOSYSTEM OF EXCELLENCE
Slide 9: Responding to Greatest Patient Need
9 RESPONDING TO GREATEST PATIENT NEED Estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths in 2020 worldwide Our broad pipeline covers 80% of the world’s cancers by incidence Head and Neck GBM NSCLC SCLC ESCC GC Bladder Prostate Sarcoma Melanoma BC CRC Ovarian Cervical HCC B
Slide 10: To Reach Billions of Patients Worldwide
10 TO REACH BILLIONS OF PATIENTS WORLDWIDE
Slide 11: R&D Capability and Portfolio Overview
11 Lai Wang, Ph.D. Global Head of R&D R&D CAPABILITY AND PORTFOLIO OVERVIEW
Slide 12: R&D Highlights
12 R&D HIGHLIGHTS R&D Engine Built at Scale to Fuel Innovation with Efficiency and Quality ‣ Highly productive preclinical research team with proven track record experienced major expansion recently ‣ Clinical development is largely CRO-free, with unique global operating model Robust Innovative Pipe
Slide 13: Science-Driven Preclinical Capabilities Experienced Major Expansion
13 SCIENCE-DRIVEN PRECLINICAL CAPABILITIES EXPERIENCED MAJOR EXPANSION RECENTLY Evolution Through Two Stages Stage 1: Establishing Core Capabilities andTalent for Early Success (2011-2018) ‣ 150-200 scientists ‣ Proven track-record with 3 internally discovered, commercially available medicines ‣ Sma
Slide 14: Internal Clinical Development Team Equipped to Run Global Development at Scale
14 AN INTERNAL CLINICAL DEVELOPMENT TEAM EQUIPPED TO RUN GLOBAL DEVELOPMENT AT SCALE ‣ Through the extensive internalization effort in the last few years, we are now largely CRO- free, allowing better control over quality, speed, cost and site / PI engagement ‣ Currently 1,700+ global clinical devel
Slide 15: Unique Operating Model to Drive Speed and Cost Advantage
15 UNIQUE OPERATING MODEL TO DRIVE SPEED & COST ADVANTAGE Source: Grants Manager median benchmark data for those countries in which BeiGene has enrolled at least one patient. Each region/country is weighted for the number patients enrolled to date. 31% 33% 41% 60% 91% 100% 0 10000 20000 30000 40000
Slide 16: Translating Science into Better and Novel Medicines
16 BRAF BTK (approved) PARP (approved) PD-1 (approved) 1st Wave (2013-2015) PD-L1 TIM-3 TIGIT BCL-2 OX40 PI3Kδ RAF Dimer 2nd Wave (2016-2020) New Waves (2021 and beyond) TRANSLATING SCIENCE INTO BETTER AND NOVEL MEDICINES Proven track record: our first decade SM, Small Molecule; mAb, Monoclonal Anti
Slide 17: Enhancing Innovation and Access Through Collaboration
17 ENHANCING INNOVATION AND ACCESS THROUGH COLLABORATION We follow the science virtually anywhere that leads to innovation – independently and via collaboration Extend our existing franchise in large indications tisle combinations: +sitra; +zanidatamab; +Leap asset NOVEL COMBINATIONS ADC mRNA NEXT-G
Slide 18: Deep Clinical and Commercial Pipeline
18 DEEP CLINICAL AND COMMERCIAL PIPELINE *Selected assets and indications are presented. **Some indications will not require a non-pivotal Ph2 clinical trial prior to beginning pivotal Ph2 or Ph3 clinical trials. ***Confirmatory clinical trials post approval are required for accelerated or condition
Slide 19: Hematology Oncology Clinical Program Update
19 William Novotny, M.D. Head of Clinical Development, Hematology HEMATOLOGY ONCOLOGY CLINICAL PROGRAM UPDATE
Slide 20: Summary of Hematology Clinical and Commercial Portfolio
20 Lymphoma/CLL Zanubrutinib (BTK) Tislelizumab (PD-1) Ociperlimab (TIGIT) BGB-11417 (BCL-2) BGB-10188 (PI3Kδ) REVLIMID SYLVANT (IL-6) AML/MDS/ALL BGB-11417 (BCL-2) BGB-A425 (TIM-3) VIDAZA BLINCYTO(R) (CD19 x CD3) AMG 330/673 (CD33 x CD3) AMG 427 (FLT3 x CD3) AMG 176/397 (MCL-1) SEA-CD70 (CD70) BGB-
Slide 21: Best-in-Class BTK Inhibitor
21 BEST-IN-CLASS BTK INHIBITOR Designed to Overcome Shortcomings of Other BTK Inhibitors Superiority Over Ibrutinib in Clinic Broad Indications Approved/In Development ‣ Reduced off-target toxicity ‣ Achieved sustained target inhibition in disease originating tissues ‣ Better efficacy ‣ Better safet
Slide 22: Better Kinase Selectivity Than Ibrutinib and Acalabrutinib
22 BETTER KINASE SELECTIVITY THAN IBRUTINIB, ACALABRUTINIB AND ITS METABOLITE M27 Zanubrutinib Ibrutinib Acalabrutinib M27 – Acala’s Metabolite ‣ Kinome analysis (370 kinases panel) at concentrations of 100 times of each molecule’s IC50 for BTK (not at 1 µM which is not adjusted for BTK potency); ac
Slide 23: Favorable Pharmacokinetic Profile Compared to Acalabrutinib and Ibrutinib
23 FAVORABLE PHARMACOKINETIC PROFILE COMPARED TO ACALABRUTINIB AND IBRUTINIB FREE DRUG CONCENTRATION TIME PROFILES RELATIVE TO IC50 Zanubrutinib Ibrutinib 560 mg QD Acalabrutinib 100 mg BID Note: These data are from separate analyses. Limitations of cross-trial comparisons apply. Source: 1. Kaptein,
Slide 24: Broad Clinical Development Programs Across Hematologic Malignancies
24 BROAD CLINICAL DEVELOPMENT PROGRAMS ACROSS MULTIPLE HEMATOLOGIC MALIGNANCIES AND BEYOND ONCOLOGY CLL/SLL WM MCL MZL DLBCL FL Mixed heme malignancies Non- oncology Company Sponsored > 1,100 > 300 >175 >100 >125 >250 Investigator P2 P2P3 P3 P2P2P3 P3 P2 P1P2 P2 P1P2 P1 P1 P2 P1P2 P2 P2 P2 P2 P2 P2
Slide 25: Zanubrutinib vs. Bendamustine + Rituximab in Treatment-Naive CLL/SLL
25 ZANUBRUTINIB VS. BENDAMUSTINE + RITUXIMAB: STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS DEMONSTRATED IN TREATMENT-NAÏVE CLL/SLL PATIENTS Treatment Naïve CLL/SLL without del(17p) (N=479) Zanubrutinib 160mg PO BID until PD (n=241) Bendamustine + Rituximab x 6 (n=238) R (1:1) for CLL/SLL Patients St
Slide 26: Zanubrutinib vs. Ibrutinib: ORR Superiority in R/R CLL/SLL
26 ZANUBRUTINIB VS. IBRUTINIB: SUPERIORITY IN OVERALL RESPONSE RATE BY INVESTIGATOR ASSESSMENT DEMONSTRATED IN RELAPSED OR REFRACTORY CLL/SLL PATIENTS for CLL/SLL Patients The PFS and OS analyses were not pre-specified. More results including safety data were presented at EHA 2021. Hillmen P et al.
Slide 27: Zanubrutinib Long-Term Follow-Up in R/R CLL/SLL
27 for CLL/SLL Patients ZANUBRUTINIB LONG-TERM FOLLOW-UP: DEEP AND DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY CLL/SLL Study Identifier: BGB-3111-AU-003, NCT02343120 Primary Endpoints: safety, RP2D Key Secondary Endpoints: ORR, CR rate, PR rate, PFS, OS, DOR Best Overall Response Sourc
Slide 28: Zanubrutinib Long-Term Follow-Up in R/R MCL
28 Phase 2 Relapsed/Refractory MCL BGB-3111-206 for MCL Patients ZANUBRUTINIB LONG-TERM FOLLOW-UP: DEEP AND DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY MCL Best Overall Response by IRC More results including safety data were presented at EHA 2021. Song Y, et al. Abstract EP789. Median
Slide 29: Zanubrutinib vs. Ibrutinib in Waldenström Macroglobulinemia
29 ZANUBRUTINIB VS. IBRUTINIB: DIRECTIONALLY FAVORABLE VGRP+CR RATE AND PFS/OS OBSERVED IN MYD88MUT WALDENSTRÖM MACROGLOBULINEMIA PATIENTS for WM Patients †Adjusted for stratification factors and age group. †† Adjusted for stratification factors and age group. p-value is for descriptive purpose only
Slide 30: Zanubrutinib vs. Ibrutinib: Improved Tolerability
30 Safety Outcomes 1) EHA 2021. Hillmen P et al. Abstract LB1900. 2) EHA 2020. Dimopoulos M et al. Abstract S225. ZANUBRUTINIB VS. IBRUTINIB: IMPROVED TOLERABILITY OF ZANUBRUTINIB COMPARED TO IBRUTINIB Category, n(%) Zanubrutinib (n=204) Ibrutinib (n=207) Any AE 195 (95.6) 205 (99.0) Grade ≥3 AE 114
Slide 31: Zanubrutinib vs. Ibrutinib: Favorable AFib/Flutter Outcomes
31 Safety Outcomes ZANUBRUTINIB VS. IBRUTINIB: FAVORABLE AFIB/FLUTTER OUTCOMES Atrial Fibrillation/Flutter Atrial Fibrillation/Flutter Hypertension Ibrutinib 10.1% Zanubrutinib 2.5% P value = 0.0014 Ibrutinib 15.3% P value = 0.0008 Zanubrutinib 2.0% P value = 0.0016 Zanubrutinib 10.9% Ibrutinib 17.3
Slide 32: Favorable Clinical Pharmacology Profile Provides Convenience for Patients
32 FAVORABLE CLINICAL PHARMACOLOGY PROFILE PROVIDES CLINICAL CONVENIENCE FOR PATIENTS 1. Brukinsa USPI 2019. 2. Ying C Ou et al. Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma, Leuk Lymphoma. 2021 3. Kun Wang et al. Comprehensive PBPK model to pr
Slide 33: Global Footprint Continues to Expand to 70+ Countries
33 2019 3 submissions ‣ MCL and CLL in CN ‣ MCL – US approval 33 2020 22 submissions ‣ 15 for MCL – CN approval ‣ 7 for WM ‣ 1 for CLL – CN approval 2021 40+ submissions planned 9-12 expected approvals ‣ 22 for MCL – 4 approvals (CA, AE, IL, CL) ‣ 13 for WM – 2 approvals (CA, CN) ‣ 8 for MZL ‣ 3 for
Slide 34: BGB-11417 (BCL-2)
34 BGB-11417 (BCL-2) Source: 1. Hu N et al. Presented at AACR 2021. Abstract 3077. ‣ Better selectivity and more potent than venetoclax, potentially translating to deeper target inhibition and better safety ‣ Potential to overcome resistance to venetoclax (G101V mutant) ‣ A key molecule in heme port
Slide 35: BGB-11417 Clinical Development
35Source: 1. Hu N et al. Presented at AACR 2021. Abstract 3077. ‣ Dose escalation ongoing for monotherapy, combination with zanubrutinib, and combination with azacitidine ‣ Clinical activity observed at the first dose level 40 mg ‣ Currently at 320 mg dose level, PK exposure at 80 mg equivalent to t
Slide 36: Zanubrutinib Is the Cornerstone Molecule for B Cell Malignancies
36 ZANUBRUTINIB, OUR BEST-IN-CLASS BTK INHIBITOR, IS THE CORNERSTONE MOLECULE FOR TREATING B CELL MALIGNANCIES ‣ More efficacious in ALPINE, safer in ALPINE and ASPEN, and more convenient than ibrutinib in clinic ‣ Great combination opportunities with Bcl-2, PI3-Kδ, Revlimid, etc. ‣ Additional new m
Slide 37: Solid Tumor Clinical Program Update
37 Yong (Ben) Ben, M.D. CMO, I/O SOLID TUMOR CLINICAL PROGRAM UPDATE
Slide 38: Summary of Solid-Tumor Clinical Portfolio
38 SUMMARY OF SOLID-TUMOR CLINICAL PORTFOLIO Marketed Products Growing Late- stage Portfolio Robust & Diversified Early Pipeline Zanidatamab HER2 Sotorasib KRAS G12C Sitravatinib multi-target TKI Ociperlimab TIGIT Antibodies OX-40, TIM-3, Bi-specifics Small Molecules HPK-1, RAF Dimer, BCL-2, PI3Kδ A
Slide 39: Differentiated PD-1 Antibody with Engineered Fc to Avoid ADCP
39 DIFFERENTIATED PD-1 ANTIBODY WITH ENGINEERED FC TO AVOID ADCP Nivo/Pembro with FcγRI-binding FcγRI- + Nivolumab Pembrolizumab CD8+ T cell CD4+ T cell - Tislelizumab FcγRI + Macrophage, Monocyte, MDSC, Dendritic cell Tislelizumab without FcγRI-binding ORR CR mPFS Camrelizumab 76.0% (95%Cl: 64.7-85
Slide 40: Tislelizumab Approvals and Ongoing Registrational Trials
40 Approval On-going Head and neck cancer MSI-H or dMMR tumors Kidney cancer Bladder cancer Hodgkin’s lymphoma Liver cancer Esophagus cancer Gastric cancer Lung cancer Melanoma Merkel cell carcinoma ‣ Approved: 1L non-sq NSCLC, 1L sq-NSCLC, 2/3L HCC, 2/3L UBC and R/R cHL ‣ Under review: 1L NPC, 2/3L
Slide 41: Strong Solid Tumor Portfolio Centered Around PD-1
41 STRONG SOLID TUMOR PORTFOLIO CENTERED AROUND PD-1 Activate T cell via stimulation agonists OX40, bispecific T cell engager Overcome PD-1 Ab resistance via TME re-modeling Sitravatinib, TIM3, PI3Kδ, DKK1 Sensitize tumors to PD-1 Ab via immunogenic cell death Zanidatamab, ZW49 Enhance PD-1 response
Slide 42: Ociperlimab (TIGIT)
42 OCIPERLIMAB (TIGIT) ‣ Positioned to be combined with tislelizumab in PD-1 sensitive tumors ‣ Mechanistically synergize with PD-1 ‣ Highly potent, with intact Fc function ‣ Fc function shown to be critical to activity preclinically ‣ One of the most advanced anti-TIGIT antibodies ‣ 200+ pts have b
Slide 43: Ociperlimab Current Clinical Development Program
43 OCIPERLIMAB (TIGIT) Phase 1a Phase 1b Phase 2 Phase 3 Untreated, locally advanced, unresectable NSCLC AdvanTIG-301, Ociperlimab + Tislelizumab + CRT 1L PD-L1+ NSCLC AdvanTIG-302, Ociperlimab + Tislelizumab 1L All-Comer NSCLC AdvanTIG-205, Ociperlimab + Tislelizumab + Chemo (planned 2H 2021) 1L LS
Slide 44: Sitravatinib Reverses PD-1 Resistance
44 Clinical Development Plan In collaboration with Mirati for Asia (ex-Japan), Australia and New Zealand Phase 1a Phase 1b Phase 2 Phase 3 Sq. & Non-sq. NSCLC, RCC, OC, Melanoma BGB-900-103, +Tislelizumab HCC, GC BGB-900-104, +Tislelizumab Sq. & Non-sq. NSCLC BGB-A317-sitravatinib-301, +Tislelizumab
Slide 45: Broad Registration Programs in NSCLC
45 NSCLC Tislelizumab Ociperlimab Sitravatinib Neoadjuvant/ Adjuvant Tisle (PD-1) + Chemo RATIONALE-315 Untreated, Locally Advanced, Unresectable Oci (TIGIT) + Tisle + CRT AdvanTIG-301 1st Line Tisle (PD-1) + Chemo (SQ) RATIONALE-307 Tisle (PD-1) + Chemo (Non-SQ) RATIONALE-304 Oci (TIGIT) + Tisle (P
Slide 46: Zanidatamab (ZW25)
46 In collaboration with Zymeworks for Asia (ex-Japan), Australia and New Zealand ‣ Target two distinct HER2 epitopes, ECD2 (trastuzumab binding domain) and ECD4 (pertuzumab binding domain) ‣ Increased tumor cell binding and enhanced HER2 internalization compared with trastuzumab ‣ Superior to trast
Slide 47: Unique OX-40 Agonist Antibody That Does Not Block Ligand-Binding
47 BGB-445 is a non-ligand-blocking OX40 Ab which retains OX-40L signal on APC cells and maximizes T cell activation BGB-445 (OX-40) Other OX40 antibodies in clinic are ligand-blocking, which lose OX-40L signal in APC cells ‣ Distinguished MOA vs. other OX-40 antibodies in the clinic ‣ Non-ligand bl
Slide 48: Potential First-in-Class HPK1 Inhibitor
48 ‣ Positioned to be combined with tislelizumab in PD-1 sensitive tumors ‣ HPK1, an intracellular immune checkpoint to negatively regulate T cell activity ‣ Based on MOA, HPK1 inhibitor will synergize with anti-PD-1 antibody ‣ HPK1 is a hard-to-hit target ‣ Challenging to achieve good potency and s
Slide 49: Deep Solid-Tumor Portfolio
49 DEEP SOLID-TUMOR PORTFOLIO Broad global clinical development programs built around tislelizumab, a differentiated PD-1 antibody Multiple combination strategies to enhance response and overcome resistance New assets entering late stage & new wave of molecules planned in the next section
Slide 50: New Modalities and Planned Pipeline
50 Lai Wang, Ph.D. Global Head of R&D NEW MODALITIES AND PLANNED PIPELINE
Slide 51: Enhance the Next Wave of Drug Discovery by Investing in New Modalities
51 ENHANCE THE NEXT WAVE OF DRUG DISCOVERY BY INVESTING IN NEW MODALITIES Traditional Small Molecule Monoclonal Ab 2011-2020
Slide 52: Enhance the Next Wave of Drug Discovery by Investing in New Modalities
52 2021 and Beyond Drug Discovery CDAC ADC Pro-Cytokine Cell Therapy BsAb/ TsAb Monoclonal Ab Traditional Small Molecule ENHANCE THE NEXT WAVE OF DRUG DISCOVERY BY INVESTING IN NEW MODALITIES CDAC, Chimeric Degradation Activating Compound; ADC, Antibody Drug Conjugate; BsAb, Bispecific Antibody; TsA
Slide 53: New Platforms: Drug Discovery Modalities
53 Drug Discovery CDAC ADC Pro-Cytokine Cell Therapy BsAb/ TsAb Monoclonal Ab Traditional Small Molecule CDAC, Chimeric Degradation Activating Compound; ADC, Antibody Drug Conjugate; BsAb, Bispecific Antibody; TsAb, Trispecific Antibody Power of New Platforms ‣ Drugging the undruggable ‣ Precise tum
Slide 54: Drugging the Undruggable: CDAC Platform
54 Differentiated from traditional small molecules by inducing target degradation ‣ Ability to target proteins with or without enzymatic activity ‣ Does not require strong and sustained target binding ‣ Eliminate the scaffolding function of the target MoA Advantage CDAC Degradation via proteosome Li
Slide 55: CDAC Differentiation: Wider Spectrum of E3 Ligases
55 Build strong capability to leverage a wider spectrum of E3 ligases: ubiquitous and tissue specific ‣ Reduce dose-limiting toxicities ‣ Overcome E3-relevant drug resistance ‣ Broaden substrate spectrum Ubiquitous Selective Restricted MDM2 CRBN Ligase A Ligase B VHL Ligase C Ligase D Ligase E Tumor
Slide 56: Broad CDAC Programs
56Heme, hematological malignancies; I-O, Immuno-oncology BCR Signaling BTK CDAC to target BTK scaffolding function Receptor Tyrosine Kinase CDAC A to treat lung cancer Cell Cycle CDAC B applicable in heme Apoptosis CDAC C applicable in heme and solid tumors TLR signaling CDAC D applicable in heme an
Slide 57: CDAC Program for B Cell Malignancies
57 ‣ Next generation BTK inhibitor to enhance BTK franchise ‣ To overcome zanubrutinib and other BTKi resistance ‣ To destroy non-kinase (scaffolding) function ‣ BGB-16673, BeiGene’s first CDAC molecule planned for clinic ‣ Good pharmacological properties ‣ Highly potent and selective ‣ Good oral bi
Slide 58: New Platforms: Drug Discovery Modalities
58 Drug Discovery CDAC ADC Pro-Cytokine Cell Therapy BsAb/ TsAb Monoclonal Ab Traditional Small Molecule CDAC, Chimeric Degradation Activating Compound; ADC, Antibody Drug Conjugate; BsAb, Bispecific Antibody; TsAb, Trispecific Antibody Power of New Platforms ‣ Drugging the undruggable ‣ Precise tum
Slide 59: Tumor Selective Targeting Approach
59 TUMOR SELECTIVE TARGETING APPROACH Tumor Associated Antigen (TAA) Toolbox 10+ TAAs are being developed, many associated with multiple tumor types Tumor Selective Immune Cell Activation ‣ Bi/Tri-specific TAA-Immune cell engager ‣ CAR-NK ‣ Immune stimulating-ADC Tumor Targeted Cell Killing ‣ Toxin
Slide 60: Activating Intra-Tumor Immune Cells: BsAb/TsAb
60 B ACTIVATING INTRA-TUMOR IMMUNE CELLS BsAb/TsAb Tumor Selective Immune Cell Activation via TAA-oriented Engagement of T/NK Receptors Llama SdAb platform Small Ab unit to be easily used in diverse formats Human SdAb phage library Bypass humanization Common light chain platform IgG-like w/o additio
Slide 61: Off-the-Shelf Tumor Targeting NK Cells
61 OFF-THE-SHELF TUMOR TARGETING NK CELLS Cell Therapy iPSC, Induced pluripotent stem cells iPSC differentiation NK function enhancement Unique CAR platforms GMP capability readiness ScFv generation IND-enabling studies Global clinical development & commercialization CollaborationMoA of CAR-NK iPSC
Slide 62: ADC: TAA Directed Missile
62 ADCTAA DIRECTED MISSILE 62 DAR, Drug Antibody Ratio NEXT GENERATION ADC designed to have superior efficacy and safety ‣ Site specific conjugation via Ambrx technology to achieve homogeneous drug antibody ratio (DAR) ‣ Innovative linker design to improve ADC biophysical property and stability, and
Slide 63: Tumor Selective Cytokine Activation
63 TUMOR SELECTIVE CYTOKINE ACTIVATION Scientific rationale ‣ Cytokine therapy to activate the immune system has been an attractive treatment modality in clinical cancer research ‣ Severe systemic toxicity hinders the broad application of immune-stimulating cytokines BeiGene’s pro-cytokine design fo
Slide 64: Preclinical Pipeline
64 Modality CDAC, Chimeric Degradation Activating Compound; ADC, Antibody Drug Conjugate; BsAb, Bispecific Antibody; TsAb, Trispecific Antibody ‣ 50+ programs ongoing, close to half with first-in-class potential ‣ 10+ planned to clinic in the next 24 months ‣ Going beyond oncology ‣ First immunology
Slide 65: Cancer-Attacking Immune Modulating Strategies
65 Stroma Stroma cell depletion Novel target H (mAb) Treg cell depletion Novel target E (mAb) Treg cell inhibition Novel target A (SM) DC expansion and activation Novel target F, G (recombinant protein) Novel target B (CDAC) Checkpoint blockade Novel target I, J (mAb) Novel target C, D (SM) Cytokine
Slide 66: Only the Beginning
66 ONLY THE BEGINNING Productive first decade establishes scientific track record ‣ Zanubrutinib and tislelizumab – set stage for leading franchises ‣ Deep portfolio built around these cornerstone assets – many moving into pivotal stage BeiGene’s R&D model stands to deliver significant innovation in
Slide 67: Closing Remarks
67 CLOSING REMARKS
Slide 68: Our True North Is Patients
68 OUR TRUE NORTH IS PATIENTS Continued innovation and expansive growth planned in next 10 years Amazing research across number of platforms with scale and talent 1 Future innovation requires deep portfolio with breadth of modalities (combinations) 2 One of the largest research organizations with ex
Slide 69: Q&A Participants
69 Angus Grant, Ph.D. Chief Business Executive Julia Wang Chief Financial Officer Q&A PARTICIPANTS Xiaodong Wang, Ph.D. Chairman of Scientific Advisory Board & Co-Founder William Novotny, M.D. Head of Clinical Development, Hematology Yong (Ben) Ben, M.D. Chief Medical Officer, Immuno-Oncology John V
Slide 70: Thank You
70 THANK YOU
Slide 71: Abbreviations
71 ABBREVIATIONS Ab Antibody Acala Acalabrutinib ADC Antibody drug conjugate ADCP Antibody-dependent cellular phagocytosis AE Adverse Event AE/UAE United Arab Emirates AFIB Atrial fibrillation ALL Acute lymphocytic leukemia ALT Alanine aminotransferase AML Acute myeloid leukemia ANZ Australia and Ne
Slide 72: Abbreviations (Cont'd)
72 ABBREVIATIONS (CONT’D) DKK1 Dickkopf-1 DLBCL Diffuse large B-cell lymphoma DLT Dose limiting toxicity dMMR Deficient Mismatch Repair DOR Duration of Response EAC Esophageal adenocarcinoma ECD2 Extracellular domain 2 ECD4 Extracellular domain 4 EHA European Hematology Association EMEA European Med
Slide 73: Abbreviations (Cont'd)
73 ABBREVIATIONS (CONT’D) MA Massachusetts mAb Monoclonal Antibody MCL Mantel Cell Lymphoma Mcl-1 Myeloid cell leukemia 1 mCRPC Metastatic Castration-Resistant Prostate Cancer MDM2 gene Murine double minute 2 gene MDS Myelodysplastic syndromes MDSC Myeloid-derived suppressor cell MEL Melanoma MM Mul
Slide 74: Abbreviations (Cont'd)
74 ABBREVIATIONS (CONT’D) QD Once a Day R&D Research and Development R/R Relapsed / Refractory R/R cHL Relapsed/refractory Classical Hodgkin Lymphoma RCC Renal Cell Carcinoma RP2D Recommended Phase 2 Dose sBLA Supplemental Biologics License Application ScFv Single-Chain Fragment Variable SCLC Small